Tirzepatide and semaglutide are the two dominant injectable GLP-1-class medications — but they work differently, produce different results, and carry different price tags. This guide breaks down every clinically meaningful difference using primary trial data so you and your doctor can make an informed choice.
glp1explained-20. We earn a small commission if you purchase through these links at no additional cost to you. This does not influence our clinical analysis. Medical Disclaimer: This article is for educational purposes only. It does not constitute medical advice. Always consult a licensed clinician before starting, switching, or stopping any medication.
| Category | Tirzepatide (Mounjaro / Zepbound) |
Semaglutide (Ozempic / Wegovy) |
|---|---|---|
| Mechanism | Dual GIP + GLP-1 agonist | GLP-1 receptor agonist only |
| Max Approved Dose | 15 mg/week (Mounjaro T2D) 15 mg/week (Zepbound obesity) |
1.0 mg/week (Ozempic T2D) 2.4 mg/week (Wegovy obesity) |
| FDA Approvals | T2D (May 2022) Obesity (Nov 2023) Obesity CV risk reduction (Mar 2025) |
T2D (Dec 2017) Obesity (Jun 2021) CV risk reduction in obesity (Mar 2024, SELECT) |
| Weight Loss % (max dose, ITT) |
~20–22% body weight (SURMOUNT-1, 72 wks) |
~14–17% body weight (STEP-1, 68 wks) |
| A1c Reduction | −2.0 to −2.3% (Mounjaro) SURPASS-2 vs Ozempic: −2.01 vs −1.86% |
−1.5 to −1.8% (Ozempic 1 mg) Wegovy: ~−1.5% in obese T2D |
| MACE / CV Data | SURPASS-CVOT: Non-inferior to Lantus; SELECT-equivalent RCT pending. SURMOUNT-MMO (HF reduction) published 2024. | LEADER (liraglutide), SUSTAIN-6, SELECT (semaglutide): 20% MACE reduction in high-CV-risk obesity (SELECT 2024). |
| List Cost / Month | ~$1,069 (Mounjaro) ~$1,059 (Zepbound) |
~$935 (Ozempic 1 mg) ~$1,349 (Wegovy 2.4 mg) |
| Availability / Shortage | FDA shortage resolved for most doses (2024–2025); compound pharmacy versions phasing out | Wegovy shortage largely resolved 2024; Ozempic broadly available |
| Nausea Rate | ~17–20% moderate/severe (vs semaglutide: similar profile) |
~20–24% moderate/severe (STEP-1 combined GI events) |
| Injection | Once weekly; auto-injector pen 2.5/5/7.5/10/12.5/15 mg doses |
Once weekly; auto-injector pen Ozempic: 0.25/0.5/1/2 mg Wegovy: 0.25→2.4 mg |
| Notable Trials | SURPASS 1–5, SURMOUNT 1–4, SURPASS-CVOT, SURMOUNT-MMO | SUSTAIN 1–10, STEP 1–5, LEADER, SELECT, FLOW (renal) |
| Who Wins Here | Weight loss · A1c · Metabolic | CV outcomes · Evidence depth · Insurance |
The most fundamental difference between these two drug classes is what they target at the receptor level.
Semaglutide is a selective agonist at the glucagon-like peptide-1 (GLP-1) receptor. It mimics the endogenous incretin hormone GLP-1, which is released from intestinal L-cells after eating. Its actions include: glucose-dependent insulin secretion (only triggers insulin when blood sugar is elevated, reducing hypoglycemia risk), suppression of glucagon release, slowed gastric emptying, and centrally-mediated appetite suppression via hypothalamic GLP-1 receptors. Semaglutide is 94% homologous to human GLP-1 and is modified with a C18 fatty acid chain that extends its half-life to approximately 7 days, enabling once-weekly dosing.
Tirzepatide is a synthetic peptide that co-activates both the GIP (glucose-dependent insulinotropic polypeptide) receptor and the GLP-1 receptor simultaneously — earning it the nickname "twincretin." GIP is the other major incretin hormone, released from duodenal K-cells. Historically, GIP was thought to be less therapeutically useful in obesity, but the combination appears synergistic: GIP receptor activation in adipose tissue enhances fat storage during caloric surplus and fat mobilization during deficit; in the brain, GIP receptors in the hypothalamus contribute additional appetite suppression beyond what GLP-1 alone provides. The net result is stronger weight loss signals than either receptor agonism alone.
The dual mechanism translates to: greater insulin secretion (both GIP and GLP-1 stimulate beta cells), greater A1c reduction, more robust weight loss, and potentially favorable effects on lipid metabolism via GIP's adipocyte actions. However, it also means more biological complexity — we have fewer decades of post-market safety data for the dual agonist compared to the GLP-1 class, which has been marketed since 2005 (exenatide).
Published in NEJM (Jastreboff et al., 2022). 2,539 adults with obesity (BMI ≥30) or overweight (BMI ≥27) with at least one weight-related comorbidity (excluding T2D). Participants were randomized to tirzepatide 5, 10, or 15 mg weekly vs placebo for 72 weeks on a calorie-restricted diet and exercise. The primary endpoint was percent change in body weight from baseline.
Results: Tirzepatide 5 mg: −15.0%; 10 mg: −19.5%; 15 mg: −22.5% vs placebo: −2.4%. All three doses achieved statistical significance (p<0.001). Notably, 91% of participants receiving 15 mg achieved ≥5% weight loss — the threshold considered clinically meaningful.
Published in NEJM (Wilding et al., 2021). 1,961 adults with obesity or overweight plus comorbidities, without T2D. Semaglutide 2.4 mg vs placebo, 68 weeks, with lifestyle intervention. Primary endpoint: percent change in body weight.
Results: Semaglutide 2.4 mg: −14.9% vs placebo: −2.4%. 86% achieved ≥5% weight loss. 32% achieved ≥20% weight loss.
SURMOUNT-1 and STEP-1 differed in duration (72 vs 68 weeks), baseline BMI, and exact lifestyle co-interventions. However, multiple network meta-analyses (including those published in JAMA, Annals of Internal Medicine, and Diabetes Care) consistently show tirzepatide 15 mg producing 5–8 percentage points more weight loss than semaglutide 2.4 mg in matched populations. The SURPASS-2 trial compared tirzepatide directly against semaglutide 1.0 mg (not 2.4 mg) in T2D patients — tirzepatide 15 mg produced −2.01% A1c reduction vs −1.86% for semaglutide, and −12.4 kg vs −6.2 kg body weight loss.
STEP-5 (semaglutide, 2 years): maintained −15.2% body weight reduction at 104 weeks. SURMOUNT-3 evaluated tirzepatide following intensive lifestyle intervention and found a remarkable −26.6% mean weight loss in the tirzepatide arm — the highest ever recorded for a pharmaceutical obesity treatment in a phase 3 RCT.
Amazon affiliate link · tag: glp1explained-20 · We earn a commission at no extra cost to you.
For patients with established cardiovascular disease or high CV risk, outcomes trial data is critically important — and here, semaglutide has a substantial head start.
SUSTAIN-6 (2016): 3,297 T2D patients with high CV risk. Semaglutide 0.5 or 1.0 mg significantly reduced the composite of cardiovascular death, nonfatal MI, or nonfatal stroke (MACE-3) by 26% vs placebo (HR 0.74, 95% CI 0.58–0.95). This drove the first cardiovascular indication for injectable semaglutide.
SELECT (2024, NEJM): 17,604 adults with obesity (BMI ≥27) and established CVD but without T2D. Semaglutide 2.4 mg (Wegovy) reduced MACE by 20% vs placebo (HR 0.80, 95% CI 0.72–0.90; p<0.001) over a median 34.2-month follow-up. This was a landmark trial — the first to demonstrate cardiovascular benefit of an anti-obesity medication in a non-T2D population. FDA granted CV risk reduction indication for Wegovy in March 2024.
FLOW (2024): Semaglutide 1.0 mg reduced renal outcomes (kidney disease progression) by 24% in T2D with chronic kidney disease — the first GLP-1 renal outcomes trial.
SURPASS-CVOT: Designed to test non-inferiority vs insulin glargine (Lantus) in T2D patients with high CV risk. Results published 2024: tirzepatide was non-inferior for MACE (met the primary endpoint), and showed a trend toward superiority, but the trial was powered for non-inferiority, not superiority. A SELECT-equivalent superiority trial in non-T2D obesity (analogous to Wegovy's SELECT) has not yet been completed for tirzepatide.
SURMOUNT-MMO: Evaluated tirzepatide in patients with obesity and heart failure with preserved ejection fraction (HFpEF). Results demonstrated significant improvements in 6-minute walk distance, quality of life, and body weight — a meaningful finding for the growing HFpEF + obesity population. FDA granted a heart failure indication for Zepbound in March 2025.
List prices for GLP-1 class drugs are notoriously uninformative. What matters is your actual out-of-pocket cost after insurance, manufacturer coupons, and pharmacy benefit manager negotiations.
The FDA shortage designation for both semaglutide and tirzepatide has been resolved (or is resolving in 2025), which means FDA-approved compounded versions are being phased out. 503B outsourcing facilities producing bulk compounded versions face enforcement action. If you are currently using compounded versions, consult your prescriber about transitioning to branded products. Quality and sterility of compounded GLP-1s varied significantly — a factor the FDA cited in enforcement decisions.
A persistent coverage asymmetry exists: T2D-branded drugs (Ozempic, Mounjaro) have much better formulary access than obesity-branded drugs (Wegovy, Zepbound). This is a policy artifact — the same molecules treating T2D are often covered on Tier 2, while their obesity-indication equivalents are excluded or on Tier 4. Medicare has historically excluded obesity drugs; the Inflation Reduction Act began changing this for cardiovascular-indicated obesity drugs post-SELECT trial.
Amazon affiliate link · tag: glp1explained-20 · We earn a commission at no extra cost to you.
No single drug is universally superior. The right choice depends on your primary indication, comorbidities, insurance, and risk tolerance.
T2D + Obesity + High CV Risk: Semaglutide has the fullest evidence set. Tirzepatide's superior glucose and weight reduction may be preferable if MACE risk is lower, but discuss with your cardiologist. Adolescents: Wegovy is FDA-approved for adolescents ≥12; Zepbound is not yet approved in this age group. Pregnancy: Both are contraindicated; discontinue at least 2 months before planned conception. Pancreatitis history: Both carry a label warning; neither is preferred over the other in this context.
| Trial | Drug | Population | Key Finding | Journal / Year |
|---|---|---|---|---|
| SURMOUNT-1 | Tirzepatide 5/10/15 mg | Obesity without T2D (n=2,539, 72 wks) | −15.0 / −19.5 / −22.5% body weight vs −2.4% placebo | NEJM 2022 |
| STEP-1 | Semaglutide 2.4 mg | Obesity without T2D (n=1,961, 68 wks) | −14.9% body weight vs −2.4% placebo; 86% ≥5% loss | NEJM 2021 |
| SURPASS-2 | Tirzepatide vs Semaglutide 1.0 mg | T2D inadequately controlled on metformin | Tirzepatide 15 mg: −2.01% A1c, −12.4 kg vs semaglutide: −1.86% A1c, −6.2 kg | NEJM 2021 |
| SELECT | Semaglutide 2.4 mg (Wegovy) | Obesity + established CVD, no T2D (n=17,604) | MACE reduced 20% vs placebo (HR 0.80; p<0.001) over 34 months | NEJM 2024 |
| SURMOUNT-MMO | Tirzepatide 10/15 mg | Obesity + HFpEF | Improved 6-min walk, KCCQ quality of life, significant weight reduction; FDA approved HF indication | NEJM 2024 |